Business Leadership


Your Business Leadership Team

Arcinova was founded in February 2016 following the acquisition of the Covance Alnwick Research Centre by Ian Shott and Paul Ryan, business partners with a track record of growing established small-and-medium-size enterprises with high growth potential in chemicals, materials, industrial biotechnology, pharmaceuticals and medical technology.

Ian is the Managing Director of the highly experienced leadership team, with Paul Ryan as Finance Director. The team is a mix of Leaders drawn from the legacy Covance organisation and new recruits:

Martin Gray, Head of CMC, and Ian Wind, Head of Facilities are both from Covance. Paul Quigley, Head of API and Bioanalytical Services, and Mark Chadwick, Head of Business Development, both joined in the first quarter of 2016 as new recruits who have previously worked with both Ian and Paul.

This senior team has extensive individual and collective international experience of working in and with biotechnology and large pharmaceutical companies. We have a good balance of site legacy and new multi-business experience of small molecule discovery and development, manufacturing and clinical trial support services.

Ian Shott

Executive Chairman and Managing Director of Arcinova

An Imperial College chemical engineering graduate, Ian has run major global businesses for a number of multi-nationals (ICI, Astra Zeneca, Lonza, Chirex and Rhodia), in the international life science industry for over 20 years. He has been based in the UK, France and Switzerland and has spent considerable periods of time in the USA, Australia and Asia.

He is a fellow of the Royal Academy of Engineering, the Institution of Chemical Engineers and the Royal Society of Chemistry. He chairs Accelerated Innovation for the Chemistry Growth Partnership with Government, is on the Governing Board of Innovate UK and chairs the Enterprise Hub at the RAEng.

Ian has a proven track record of transforming technology-based businesses to deliver exceptional results, by a combination of break-out development, culture change, organic growth, internal re-engineering and external merger, acquisition and divestment.

"I’m an entrepreneur and an engineer. I love working with small businesses with untapped potential. We use our knowledge, experience, tools, judgement and global networks to create value and sustainable growth."

Paul Ryan

Finance Director of Arcinova

With Ian Shott, Paul has a fifteen-year history running businesses in the global Pharmaceutical Industry from the North East of the UK, with close connections to local universities and involvement in a number of business development and economic regeneration projects in the region.

Paul is a graduate of Newcastle University and KPMG-trained Chartered Accountant.

He has developed his technical, managerial and leadership skills during two decades in senior finance roles in international organisations (public, private and private equity backed) in the food, energy services and pharmaceutical industry.

"I get a real buzz from working with a high growth potential business, where I can use my deep financial experience and extensive tool kit in a disciplined, structured and focused way to help achieve significant results quickly."

Paul Quigley

Head of API Development and Bioanalytical Services

Paul is an organic chemist with a wealth of experience driving small molecule process development and project management. 

Previous relevant employers include Tracerco (Johnson Matthey), Shasun Pharma Solutions, Clariant Life Sciences and Schering-Plough Corp.

Paul was educated at Dublin University where he obtained a degree and a PhD in Organic Chemistry, with an MBA from Warwick Business School.

“I enjoy building, directing and coaching technical teams to drive the commercial application of technology and enhance value for an organisation and achieve excellent results for customers.”


Martin Gray

Head of CMC

Having started his working life as an analytical scientist, Martin has spent more than 30 years in the pharmaceutical drug development business.

Previous positions have included head of small molecule CMC operations in the UK for Covance Laboratories, site head of CMC and site head of Analytical Sciences for Sanofi-Aventis.

Martin holds a degree in Chemistry from the University of Southampton and a masters degree in Advanced Analytical Chemistry from Northumbria University.

“Having worked in both major Pharma and contract organisations, it allows me to look at client problems and needs from a range of perspectives. I particularly enjoy bringing this experience into a working environment where there is a clear link between ideas and their rapid translation into CMC solutions for all concerned”


Ian Wind

Head of Facilities

Ian is a Chartered Engineer, having had roles with responsibility for Maintenance, Engineering, Facilities Management and Health & Safety within the Brewing, Electronics, Packaging and Pharmaceutical industries.

Ian has a degree in Mechanical Engineering from Sunderland University and a MBA from Northumbria University. 

"I gain the most satisfaction from developing teams and strategic planning as well as looking for ways to continually improve the efficiency and effectiveness of the business."

Mark Chadwick

Head of Business Development

Originally a molecular biologist, Mark has spent 18 years in the drug discovery and development industry in both project management and commercial roles.  Previous relevant positions include CEO at AIM-listed Physiomics plc, VP Business Development at Excelsyn and Director of Commercial Operations at BioFocus. 

Mark holds a degree in Genetics from the University of Nottingham, a PhD in Molecular Biology from the University of Newcastle and an MBA from Imperial College London.

"Throughout my career I have always been passionate about providing drug discovery and development services to customers. I gain a great deal of satisfaction from collaborating with biotechnology and pharmaceutical companies and being part of a team who deliver solutions that are often of critical importance to our partners."